On the network pharmacology side, Casas et al. (2019b) used a bottom-up “target-to-data” approach and chose NOX4 (NADPH oxidase 4), a potent producer of superoxide following the onset of ischemic stroke, as the primary protein target to study potential combination therapies for stroke. The gene discussed is NOX4; the disease is ischemic stroke.